The estimated Net Worth of Alexander Schornstein is at least $12 Milione dollars as of 3 July 2024. Alexander Schornstein owns over 9,000 units of Assembly Biosciences Inc stock worth over $12,046,304 and over the last few years Alexander sold ASMB stock worth over $0.
Alexander has made over 3 trades of the Assembly Biosciences Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently Alexander bought 9,000 units of ASMB stock worth $111,600 on 3 July 2024.
The largest trade Alexander's ever made was buying 645,080 units of Assembly Biosciences Inc stock on 17 January 2024 worth over $509,613. On average, Alexander trades about 351,360 units every 75 days since 2023. As of 3 July 2024 Alexander still owns at least 693,113 units of Assembly Biosciences Inc stock.
You can see the complete history of Alexander Schornstein stock trades at the bottom of the page.
Alexander's mailing address filed with the SEC is KAISER-FRIEDRICH-ALLEE 2, , AACHEN, 2M, 52074.
Over the last 10 years, insiders at Assembly Biosciences Inc have traded over $1,523,622 worth of Assembly Biosciences Inc stock and bought 1,245,980 units worth $1,060,065 . The most active insiders traders include Sciences, Inc. Gilead, Myron Z Holubiak e Helen Susan Kim. On average, Assembly Biosciences Inc executives and independent directors trade stock every 46 days with the average trade being worth of $389,399. The most recent stock trade was executed by Nicole S White on 2 August 2024, trading 785 units of ASMB stock currently worth $11,171.
assembly biosciences, inc. (nasdaq: asmb) is a public clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of hepatitis b virus (hbv) infection and novel oral live biotherapeutics for disorders associated with the microbiome. assembly is developing two innovative platform programs: an hbv program advancing a new class of oral therapeutics for the treatment of hepatitis b virus (hbv) infection and a microbiome program developing novel oral live biotherapeutics designed to address diseases associated with the microbiome. assembly’s hbv program is advancing multiple drug candidates with the aim of increasing cure rates in patients with chronic hbv. the company's microbiome program consists of a fully integrated platform that includes a robust strain identification and selection process, methods for strain isolation and growth under current good manufacturing practices and a patent-pending delivery system, gemicel®, which allows for targeted ora
Assembly Biosciences Inc executives and other stock owners filed with the SEC include: